Targets › CLN2
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.
Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. (UniProt, O14773)
Open in Phaseline: the race on CLN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tern Therapeutics | TTX-381 AAV9-mediated hCLN2 gene therapy | CLN2 | Phase 1 | Neuronal Ceroid Lipofuscinosis Type 2 | Dec 2026 |
Neuronal Ceroid Lipofuscinosis Type 2 (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.